A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
About the study
A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a prior HER2-directed agent and fluoropyrimidine- or platinum-containing chemotherapy (2nd-line or 3rd-line)
- Adequate Bone Marrow Function.
- Adequate Renal & Liver Function.
- Adequate Performance Status
EXCLUSION CRITERIA
Exclusion Criteria:
- Patients with known symptomatic CNS metastases or leptomeningeal disease requiring steroids.
- Prior treatment with any anti-CD47 or anti-SIRPα agent.
- Prior treatment with ramucirumab.
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Gastric Cancer,Gastroesophageal Junction Adenocarcinoma,Gastric Adenocarcinoma
Age (in years)
18+
Phase
Phase 2/Phase 3
Participants needed
450
Est. Completion Date
Aug 31, 2028
Treatment type
Interventional
Sponsor
ALX Oncology Inc.
ClinicalTrials.gov identifier
NCT05002127
Study number
AT148006
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?